Dipanjan Banerjee, MD
Cardiovascular Disease · Honolulu, HINPI 1295787299
Payments from drug & device makers
Across 482 payments — averaging $937.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$247K
- Endotronix, Inc.$74K
- Pfizer$28K
- Bridgebio Pharma, Inc.$20K
- Boston Scientific$16K
- Boehringer Ingelheim$14K
- plus $53K from 29 others
What the payments were for
- Consulting fees$6,3502%
- Speaking & faculty fees$253,67277%
- Travel & lodging$54,30216%
- Food & beverage$17,0225%
- Education$1290%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 186 | $247,195 |
| Endotronix, Inc. | 6 | $73,561 |
| Pfizer | 28 | $28,436 |
| Bridgebio Pharma, Inc. | 25 | $20,268 |
| Boston Scientific | 9 | $16,084 |
| Boehringer Ingelheim | 52 | $13,686 |
| Medtronic(2 entities) | 8 | $10,635 |
| Bayer | 19 | $9,306 |
| Abbott | 32 | $8,444 |
| AstraZeneca | 10 | $7,923 |
| Alnylam Pharmaceuticals Inc. | 13 | $5,815 |
| Abiomed | 15 | $3,703 |
| Novartis | 2 | $3,262 |
| Lilly USA, LLC | 2 | $779 |
| Cvrx, Inc. | 5 | $401 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 14 | $292 |
| Amgen | 8 | $291 |
| Novo Nordisk | 8 | $201 |
| Vifor Pharma, Inc. | 3 | $190 |
| Sobi, Inc | 2 | $170 |
| Livanova USA, Inc. | 2 | $161 |
| Paragonix Technologies, Inc. | 3 | $160 |
| Akcea Therapeutics, Inc. | 6 | $156 |
| Atricure, Inc. | 1 | $149 |
| Kls-martin L.p. | 1 | $99 |
| Merck | 4 | $85 |
| Amarin Pharma, Inc. | 3 | $59 |
| Baxter Healthcare | 3 | $56 |
| Johnson & Johnson | 2 | $53 |
| Regeneron Healthcare Solutions, Inc. | 2 | $48 |
| Lexicon Pharmaceuticals, Inc. | 2 | $47 |
| Scpharmaceuticals Inc. | 2 | $44 |
| Lantheus Medical Imaging, Inc. | 2 | $33 |
| Actelion Pharmaceuticals US, Inc. | 1 | $24 |
| Inspire Medical Systems, Inc. | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAMZYOS$223,815
- VYNDAQEL$27,935
- Attruby$19,921
- JARDIANCE$13,142
- HeartWare HVAD$10,344
- Kerendia$8,866
- MitraClip$6,916
- ONPATTRO$5,242
- Impella$3,410
- RESONATE$285
- Mitra Clip system$248
- Barostim Neo System$209
- COBALT DR MRI SURESCAN$175
- CORDELLA PULOMONARY ARTERY PRESSURE SENSOR$157
- TEGSEDI$150
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$150
- LARIAT SUTURE DELIVERY DEVICE$149
- CentriMag$141
- HeartMate 3 Left Ventricular Assist Device$128
- LUX-Dx Insertable Cardiac Monitor$125
How this compares
$451,838 in reported general payments places this provider in the 95th percentile of 73 cardiovascular disease providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 15 | $365,511 |
| EntrestoSacubitril/Valsartan | 69 | $112,380 |
| JardianceEmpagliflozin | 56 | $82,340 |
| EliquisApixaban | 30 | $41,430 |
| Sirolimus | 23 | $6,311 |
| Tacrolimus | 14 | $2,658 |
| Metoprolol Succinate | 88 | $2,228 |
| Atorvastatin Calcium | 43 | $1,511 |
| Losartan Potassium | 59 | $1,305 |
| Rosuvastatin Calcium | 24 | $1,235 |
| Digoxin | 26 | $803 |
| Furosemide | 56 | $410 |
| Carvedilol | 34 | $399 |
| Spironolactone | 46 | $264 |
| Lisinopril | 20 | $185 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $28,436 | $406,94145 claims |
| NovartisEntresto | $3,262 | $112,38069 claims |
| Boehringer IngelheimJardiance | $13,686 | $82,34056 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 73 cardiovascular disease providers in Hawaii.
Other cardiovascular disease in Honolulu
- Joana MagnoHonolulu$23K
- Hingson ChunHonolulu$23K
- William DangHonolulu$16K
- Edward ShenHonolulu$12K
- Se Kon WonHonolulu$11K
- Wesley KaiHonolulu$10K
- Calvin WongHonolulu$8K
- Abdulelah NuqaliHonolulu$7K
- Mahdi Veillet-ChowdhuryHonolulu$7K
- Nath LimpruttidhamHonolulu$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.